MARKET

CRL

CRL

Charles Riv Labs Intl Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

223.48
+0.13
+0.06%
After Hours: 225.00 +1.52 +0.68% 16:10 05/25 EDT
OPEN
221.90
PREV CLOSE
223.35
HIGH
225.39
LOW
219.18
VOLUME
403.87K
TURNOVER
0
52 WEEK HIGH
460.21
52 WEEK LOW
217.20
MARKET CAP
11.35B
P/E (TTM)
27.23
1D
5D
1M
3M
1Y
5Y
Charles River Labs to add 500 more jobs with Ashland expansion project
The contract research organization is adding a 200,000-square-foot expansion to increase capacity for client work and enhance employees' experience.
American City Business Journals · 11h ago
Analyst Ratings for Charles River
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings:
Benzinga · 1d ago
Charles River Laboratories International, Inc.'s (NYSE:CRL) Intrinsic Value Is Potentially 87% Above Its Share Price
Does the May share price for Charles River Laboratories International, Inc. ( NYSE:CRL ) reflect what it's really...
Simply Wall St. · 1d ago
Guggenheim Initiates Coverage on Charles River Laboratories International With Neutral Rating
MT Newswires · 2d ago
Charles River's Return On Capital Employed Overview
Pulled from Benzinga Pro data, Charles River (NYSE:CRL) showed a loss in earnings since Q4, totaling $95.23 million. Sales, on the other hand, increased by 0.98% to $913.93 million during Q1.
Benzinga · 05/17 14:06
Here's Why You Should Retain Charles River (CRL) Stock for Now
Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
Zacks · 05/16 15:47
Most likely large-cap and small-cap merger candidates -BofA
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based
Seekingalpha · 05/15 15:42
Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Zacks · 05/10 14:48
More
No Data
Learn about the latest financial forecast of CRL. Analyze the recent business situations of Charles Riv Labs Intl Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
53.33%Buy
6.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRL stock price target is 332.18 with a high estimate of 378.00 and a low estimate of 280.00.
High378.00
Average332.18
Low280.00
Current 223.48
EPS
Actual
Estimate
0.711.412.112.82
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 805
Institutional Holdings: 52.72M
% Owned: 103.77%
Shares Outstanding: 50.80M
TypeInstitutionsShares
Increased
254
4.51M
New
60
404.70K
Decreased
219
3.84M
Sold Out
110
566.08K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Foster
Chief Financial Officer/Executive Vice President
Flavia Pease
Chief Operating Officer/Executive Vice President
Birgit Girshick
Chief Human Resource Officer/Executive Vice President
Victoria Creamer
Executive Vice President
William Barbo
Executive Vice President
Joseph LaPlume
Director
Martin Mackay
Independent Director
Nancy Andrews
Independent Director
Robert Bertolini
Independent Director
Deborah Kochevar
Independent Director
George Llado
Independent Director
George Massaro
Independent Director
Richard Reese
Independent Director
Richard Wallman
Independent Director
Virginia Wilson
No Data
No Data
About CRL
Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company provides products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions in research and drug development. The Company operates through two segments: Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). The DSA segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions, and Avian Vaccine Services.

Webull offers kinds of Charles River Laboratories Intl. Inc stock information, including NYSE:CRL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRL stock methods without spending real money on the virtual paper trading platform.